

**Unaudited Financial Results for the Quarter / Nine Months Ended on 31st December, 2014**

( in lacs )

Particulars	Quarter Ended on			Nine Months Ended on		Year Ended on
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income from operations</b>						
(a) Net Sales / Income from operations (Net of excise duty)	574.32	768.46	551.22	2,185.40	2,181.34	3,131.36
(b) Other Operating Income	7.50	7.03	2.67	28.09	9.17	19.32
<b>Total income from operations (net)</b>	<b>581.82</b>	<b>775.49</b>	<b>553.89</b>	<b>2,213.49</b>	<b>2,190.51</b>	<b>3,150.68</b>
<b>2. Expenses</b>						
(a) Cost of materials consumed	301.55	379.38	328.21	1,183.70	1,161.23	1,706.85
(b) Purchases of traded goods	-	-	1.04	-	382.25	382.25
(c) Changes in inventories of finished goods, work - in - progress and stock - in - trade	(7.20)	59.10	30.01	43.65	(66.85)	(101.06)
(d) Employee benefits expense	64.19	63.61	60.22	196.77	183.94	249.54
(e) Depreciation and amortisation expense	27.55	27.54	28.52	82.63	85.55	108.63
(f) Power and fuel	26.85	34.99	40.50	111.46	131.69	176.77
(g) Other expenditure	83.60	76.42	52.95	229.96	177.48	324.39
<b>Total expenses</b>	<b>496.54</b>	<b>641.04</b>	<b>541.45</b>	<b>1,848.17</b>	<b>2,055.29</b>	<b>2,847.37</b>
<b>3 Profit / (Loss) from operations before other income, finance costs &amp; exceptional items (1-2)</b>	<b>85.28</b>	<b>134.45</b>	<b>12.44</b>	<b>365.32</b>	<b>135.22</b>	<b>303.31</b>
4. Other Income	20.14	75.61	22.19	102.28	169.14	182.60
<b>5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>105.42</b>	<b>210.06</b>	<b>34.63</b>	<b>467.60</b>	<b>304.36</b>	<b>485.91</b>
6. Finance costs	0.48	1.77	4.55	8.60	19.52	25.95
<b>7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>104.94</b>	<b>208.29</b>	<b>30.08</b>	<b>459.00</b>	<b>284.84</b>	<b>459.96</b>
8. Exceptional Items	-	-	-	-	-	-
<b>9. Profit / (Loss) from ordinary activities before tax (7+8)</b>	<b>104.94</b>	<b>208.29</b>	<b>30.08</b>	<b>459.00</b>	<b>284.84</b>	<b>459.96</b>
10. Tax expense	21.00	32.00	6.00	82.00	34.00	172.57
<b>11. Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>83.94</b>	<b>176.29</b>	<b>24.08</b>	<b>377.00</b>	<b>250.84</b>	<b>287.39</b>
12. Extraordinary Item (net of tax expense NIL)	-	-	-	-	-	-
<b>13. Net Profit / (Loss) for the period (11-12)</b>	<b>83.94</b>	<b>176.29</b>	<b>24.08</b>	<b>377.00</b>	<b>250.84</b>	<b>287.39</b>
14. Paid - up equity share capital (Face Value of 10/- each)	388.32	388.32	388.32	388.32	388.32	388.32
15. Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	2,985.57
<b>16. i Earnings per share (before extraordinary items) (of 10/- each) (not annualised)</b>						
(a) Basic	2.16	4.54	0.62	9.71	6.46	7.40
(b) Diluted	2.16	4.54	0.62	9.71	6.46	7.40
<b>16. ii Earnings per share (after extraordinary items) (of 10/- each) (not annualised)</b>						
(a) Basic	2.16	4.54	0.62	9.71	6.46	7.40
(b) Diluted	2.16	4.54	0.62	9.71	6.46	7.40
<b>A. PARTICULARS OF SHAREHOLDING</b>						
<b>1 Public shareholdings</b>						
- Number of shares	1,035,230	1,035,230	1,035,230	1,035,230	1,035,230	1,035,230
- Percentage of shareholding	26.66	26.66	26.66	26.66	26.66	26.66
<b>2 Promoters and promoter group shareholding</b>						
(a) Pledged / Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
(b) Non - encumbered						
- Number of shares	2,847,945	2,847,945	2,847,945	2,847,945	2,847,945	2,847,945
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100 %	100 %	100 %	100 %	100 %	100 %
- Percentage of shares (as a % of the total share capital of the Company)	73.34 %	73.34 %	73.34 %	73.34 %	73.34 %	73.34 %

KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED

Regd. Office : C - 4, Gillander House, 8 Netaji Subhas Road, Kolkata - 700 001  
 Phone : 2230 - 2331 (6 lines), Fax No. 2242 - 7286, E.mail : hokothari@yahoo.com  
 Website : www.kothariphyto.com, CIN : L15491WB1897PLC001365

PARTICULARS		Quarter ended 31/12/2014
<b>B.</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed off during the quarter	2
	Remaining unresolved at the end of the quarter	Nil

Unaudited Segmentwise Revenue, Results and Capital Employed for the Quarter / Nine Months Ended on 31st December, 2014

( in lacs )

Particulars	Quarter Ended on			Nine Months Ended on		Year Ended on
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b> (net sale / income from each segment should be disclosed under this head)						
(a) Bulk Drugs	320.59	463.75	218.89	1,178.05	727.54	1,300.56
(b) Chemicals	261.23	310.19	335.00	1,025.20	1,077.53	1,464.68
(c) Trading	0.00	1.55	-	10.24	385.44	385.44
<b>Total</b>	<b>581.82</b>	<b>775.49</b>	<b>553.89</b>	<b>2,213.49</b>	<b>2,190.51</b>	<b>3,150.68</b>
<b>Less: Inter Segment Revenue</b>	-	-	-	-	-	-
<b>Net Sales / Income from Operations</b>	<b>581.82</b>	<b>775.49</b>	<b>553.89</b>	<b>2,213.49</b>	<b>2,190.51</b>	<b>3,150.68</b>
<b>2. Segment Results</b> (Profit / (Loss) before tax and interest from each segment)						
(a) Bulk Drugs	128.64	161.91	46.12	457.13	231.81	443.00
(b) Chemicals	6.92	6.52	2.16	17.65	4.43	(0.84)
(c) Trading	(0.32)	1.29	(1.32)	9.26	1.49	1.20
<b>Total</b>	<b>135.24</b>	<b>169.72</b>	<b>46.96</b>	<b>484.04</b>	<b>237.73</b>	<b>443.36</b>
Unallocated	(2.25)	67.89	16.21	66.20	152.19	151.18
<b>Total</b>	<b>132.99</b>	<b>237.61</b>	<b>63.17</b>	<b>550.24</b>	<b>389.92</b>	<b>594.54</b>
Less: i) Interest	0.48	1.77	4.55	8.60	19.52	25.95
ii) Other Un-allocable Expenditure net off unallocable income	27.57	27.55	28.54	82.64	85.56	108.63
<b>Total Profit / (Loss) Before Tax</b>	<b>104.94</b>	<b>208.29</b>	<b>30.08</b>	<b>459.00</b>	<b>284.84</b>	<b>459.96</b>
<b>3. Capital Employed</b> (Segment Assets - Segment Liabilities)						
(a) Bulk Drugs	2,017.03	1,952.25	1,585.71	2,017.03	1,585.71	1,784.80
(b) Chemicals	539.80	541.58	550.09	539.80	550.09	539.41
(c) Trading	1.68	2.00	1.69	1.68	1.69	1.41
(d) Unallocated	1,192.38	1,171.11	1,290.71	1,192.38	1,290.71	1,048.27
<b>Total</b>	<b>3,750.89</b>	<b>3,666.94</b>	<b>3,428.20</b>	<b>3,750.89</b>	<b>3,428.20</b>	<b>3,373.89</b>

- Notes**
- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 13th February, 2015.
  - Limited Review of the above Unaudited Financial Results has been carried out by the Statutory Auditors of the Company.
  - Previous period's figures have been regrouped and rearranged wherever necessary.